BOARD OF DIRECTORS

Taylor Crouch,

Chief Executive Officer and President, Organovo

Mr. Crouch has over 25 years of experience building and leading technology, expertise and product-based companies in the life sciences and biotech industries. For more than seven years, he has managed and served as an operational investor in a group of leading clinical research site companies. Specifically, Mr. Crouch served as Chief Executive Officer at eStudySite, a position he held from January 2009 to June 2016; as Executive Chairman of Meridien Research from December 2013 to September 2016; and as a Director of the National Research Institute from September 2011 through July 2016. He was instrumental in building these three sister companies, and helping them to achieve significant and profitable growth and to become recognized leaders in their respective fields of infectious disease, CNS disorders and metabolic disease. Prior to this, Mr. Crouch served as Senior Vice President of Operations/President International at Ligand Pharmaceuticals from 2005 to 2007, with responsibilities for new business development, technical operations, international sales and clinical research. Prior to Ligand, he was President and Chief Operating Officer of Discovery Partners International (NASDAQ: formerly DPII – a large drug discovery services and technology provider). Earlier in his career, he was Chief Executive Officer of Variagenics (NASDAQ: formerly VGNX – a leading pharmacogenomics company), Senior Vice President of Marketing and Sales at Parexel – a global CRO, and he also held international management positions in new product development and commercialization at Pfizer and Schering Plough. Mr. Crouch holds a BSE in chemical engineering, cum laude, from Princeton University and an MBA in international marketing and finance from the University of Chicago.

Sharon Collins Presnell, Ph.D.,

President of Samsara, and Chief Technology Officer of Organovo

Dr. Presnell has more than 16 years of experience in the leadership of product-focused R&D. As an assistant professor at the University of North Carolina at Chapel Hill, Dr. Presnell’s research in liver and prostate biology and carcinogenesis produced cell- and tissue-based technologies that were industry-funded or outlicensed for industrial applications. She joined Becton Dickinson (BD) in 2001 and played a key role in the early discovery and development of cell-based tools and reagents for BD’s life sciences portfolio. At BD, she grew and led a large multi-disciplinary team to build and validate screening platforms and products for cell growth, differentiation, and characterization and secured revenue-generating commercial partnerships with pharma partners. Sharon joined Tengion, Inc. in 2007, and as the Senior Vice President of Regenerative Medicine Research, was responsible for leading the discovery and early development of Tengion’s Neo-Kidney Augment™, a clinical-stage cell-based therapy for patients with chronic kidney disease. As the Chief Technology Officer at Organovo, Dr. Presnell has led the growth and development of the R&D organization, including evolution of the company’s technology portfolio, and has played an instrumental role in securing funds in support of corporate growth initiatives. Sharon holds a PhD in pathology from the Medical College of Virginia. Dr. Presnell is a member of the American Society of Investigative Pathology, the American Society of Nephrology, and the International Society of Cell Transplantation, serves on the editorial board of the journal ‘3D Printing and Additive Manufacturing’, and remains active as an NIH reviewer as an industry representative in the biomedical engineering space.

Jennifer Kinsbruner Bush, JD,

General Counsel, Corporate Secretary and Compliance Officer

Ms. Bush has more than 15 years of intellectual property, corporate legal, regulatory, compliance, and transactional experience. Prior to joining Organovo, Ms. Bush held positions of increasing responsibility at Broadcom Corp., where she was most recently Associate General Counsel. Before joining Broadcom, Ms. Bush served as Associate General Counsel of DivX, Inc. prior to its acquisition by Sonic Solutions in October 2010. Earlier in her career, Ms. Bush was a Principal at Fish & Richardson, from 2001 to January 2010 where she represented clients focused on a variety of technologies, including in the areas of medical devices, life sciences, software, and consumer products. Ms. Bush received a J.D. from Yale Law School and an A.B. in history and Latin American Studies from Princeton University.